- Home
- NYC vs CNSY Comparison
NYC vs CNSY Comparison
Compare NYC & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | CNSY |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 20.6M |
| IPO Year | 2014 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NYC | CNSY |
|---|---|---|
| Price | $5.91 | $0.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $27.75 |
| AVG Volume (30 Days) | 3.3K | ★ 1.6M |
| Earning Date | 11-13-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 85.28 | ★ 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,213,000.00 |
| Revenue This Year | $35.25 | N/A |
| Revenue Next Year | N/A | $414.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $0.78 |
| 52 Week High | $13.97 | $4.25 |
Technical Indicators
Market Signals| Indicator | NYC | CNSY |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 19.89 |
| Support Level | $5.51 | N/A |
| Resistance Level | $6.28 | $2.28 |
| Average True Range (ATR) | 0.22 | 0.38 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 3.33 | 1.65 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About CNSY Cerenome Inc. Common Stock
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.